Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)14.42
  • Today's Change-0.84 / -5.50%
  • Shares traded3.02m
  • 1 Year change+93.82%
  • Beta1.4480
Data delayed at least 15 minutes, as of Mar 03 2026 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 26-Feb-26
Select bar for recommendation details.
Recommendations26-Feb-26
Buy3
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in CNY

The 2 analysts offering 12 month price targets for Ascletis Pharma Inc have a median target of 22.84, with a high estimate of 31.95 and a low estimate of 13.74. The median estimate represents a 58.41% increase from the last price of 14.42.
High121.5%31.95
Med58.4%22.84
Low-4.7%13.74

Earnings history & estimates in CNY

Ascletis Pharma Inc reported annual 2024 losses of -0.301 per share on Mar 26, 2025.
Average growth rate-42.31%
More ▼

Revenue history & estimates in CNY

Ascletis Pharma Inc. had revenues for the full year 2024 of 1.28m. This was 97.73% below the prior year's results.
Average growth rate-0.78%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.